You are here

  • Home
  • Archive
  • Volume 28, Issue 2
  • FDA’s dilemma with the aducanumab approval: public pressure and hope, surrogate markers and efficacy, and possible next steps

Article info

Article menu
Download PDFPDF
EBM analysis
FDA’s dilemma with the aducanumab approval: public pressure and hope, surrogate markers and efficacy, and possible next steps

Authors

  1. Correspondence to Dr John G Rizk, University of Maryland Baltimore, Baltimore, Maryland, USA; john.rizk{at}umaryland.edu
View Full Text

Citation

Rizk JG, Lewin JC
FDA’s dilemma with the aducanumab approval: public pressure and hope, surrogate markers and efficacy, and possible next steps
BMJ Evidence-Based Medicine 2023;28:78-82.

Publication history

  • Accepted April 2, 2022
  • First published April 21, 2022.
Online issue publication 
March 23, 2023

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.